Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis

/PRNewswire/ -- MyHealthTeam, creator of the largest and fastest-growing social networks for people living with chronic health conditions, today launched...

ARQT : 10.80 (-0.55%)
Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study

Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.

AVEO : 15.00 (unch)
ETON : 4.04 (+1.51%)
ARQT : 10.80 (-0.55%)
IMCR : 47.36 (-3.70%)
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Misses Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -22.73% and 27.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

ARQT : 10.80 (-0.55%)
ANGN : 0.5431 (+4.44%)
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million

/PRNewswire/ -- LifeArc today announced that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing...

ARQT : 10.80 (-0.55%)
NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING

/PRNewswire/ -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) today announced the launch of an educational campaign designed to raise awareness about the...

ARQT : 10.80 (-0.55%)
Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very...

ARQT : 10.80 (-0.55%)
Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update

Received U.S. Food and Drug Administration (FDA) approval for ZORYVE™ (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including...

ARQT : 10.80 (-0.55%)
Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trialEnrollment continues in INTEGUMENT-2 with topline data...

ARQT : 10.80 (-0.55%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical...

ARQT : 10.80 (-0.55%)
Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage...

ARQT : 10.80 (-0.55%)

Barchart Exclusives

Don’t Let GameStop’s Unusual Options Activity Cloud Your Judgement
GameStop announced a small profit on Tuesday after the close. Wednesday’s stock and options volume went through the roof. GameStop has a long way to go before it’s worth owning for the long haul. Don’t let yesterday’s activity cloud your judgment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar